Market Cap 75.35B
Revenue (ttm) 14.34B
Net Income (ttm) 4.50B
EPS (ttm) N/A
PE Ratio 19.24
Forward PE 19.28
Profit Margin 31.41%
Debt to Equity Ratio 0.06
Volume 824,400
Avg Vol 682,502
Day's Range N/A - N/A
Shares Out 105.72M
Stochastic %K 90%
Beta 0.30
Analysts Strong Sell
Price Target $874.75

Company Profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascul...

Industry: Biotechnology
Sector: Healthcare
Phone: 914 847 7000
Address:
777 Old Saw Mill River Road, Tarrytown, United States
OfficialStocktwitsUser
OfficialStocktwitsUser May. 13 at 4:41 AM
$REGN RSI: 43.88, MACD: -10.9968 Vol: 22.57, MA20: 728.76, MA50: 746.12 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
bnglao24
bnglao24 May. 12 at 12:24 PM
$IMMX Mgt is comparing nxc-201 to Abbvie’s ententamig in the corporate presentation but looks like they should be aware of $REGN linvoseltamab which is slated for an ASCO oral presentation in a few weeks (also a bispecific) https://www.asco.org/abstracts-presentations/268071 Abstract made public next Thursday 👀
2 · Reply
NewEarth
NewEarth May. 11 at 10:21 PM
0 · Reply
BillionerOfKing
BillionerOfKing May. 11 at 3:11 PM
$REGN Current Stock Price: $718.85 Contracts to trade: $720.0 REGN May 15 2026 Call Entry: $12.40 Exit: $16.12 ROI: 30% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
PickAlpha
PickAlpha May. 11 at 11:59 AM
3/6: MoonLake (MLTX) reports positive final pre‑BLA FDA meeting for sonelokimab (SLK) in hidradenitis suppurativa; plans BLA submission end‑Sep 2026 and seeks Priority Review. $MLTX $XBI $IBB $REGN $VRTX
0 · Reply
WallStJesus
WallStJesus May. 10 at 6:17 PM
$REGN 💉
0 · Reply
Kool_Aid_Mann
Kool_Aid_Mann May. 8 at 7:53 PM
$VRTX $ALNY $REGN Join MNKD as they approach their May 29th pediatric PDUFA!! This is the one that they have been waiting for for 12 years. Lots of delays, but finally here and likely to be the milestone trigger for a big cash deal with big pharma! On top of that, they just got back the green light for Treprostinil DPI in IPF which had them previously trading over $6 until a spat with their partner UTHR. Now, not only is everything copacetic again, but they have also just announced a new molecule colloboration with bigger potential than Trep, Ralinpag DPI! Big royalty model like $LGND But wait, there's more, there is another PDUFA ahead for them for furoscix on July 26th, that will approve a new auto injector that will make this product best in class and reduce COGs by 70% to create massive profits. And lets not forget that nintedabib DPI just finished 1b and is prime for an upfront cash deal! $VCYT Fireworks ahead, fight the Citadel!
0 · Reply
WallStJesus
WallStJesus May. 8 at 2:43 PM
$REGN NOV BULL SWEEPER DETECTED
0 · Reply
NewEarth
NewEarth May. 8 at 2:34 PM
$NTLA $BEAM $EDIT $REGN $PRME Jennifer and Intellia are going to hold the market of all these treatments
0 · Reply
judgeyoung2
judgeyoung2 May. 7 at 7:26 PM
$REGN if fianlimab is disappointing then they’ll prolly drop it on a friday morning
1 · Reply
Latest News on REGN
Regeneron price target raised to $995 from $975 at Guggenheim

2026-05-01T11:11:38.000Z - 12 days ago

Regeneron price target raised to $995 from $975 at Guggenheim


Regeneron price target lowered to $796 from $801 at Truist

2026-04-30T17:04:53.000Z - 12 days ago

Regeneron price target lowered to $796 from $801 at Truist


Regeneron price target lowered to $917 from $923 at Barclays

2026-04-30T09:52:25.000Z - 13 days ago

Regeneron price target lowered to $917 from $923 at Barclays


Regeneron Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:30 AM EDT - 14 days ago

Regeneron Pharmaceuticals Earnings Call Transcript: Q1 2026


Regeneron CEO on deal with Trump admin to lower drug prices

Apr 24, 2026, 10:30 AM EDT - 19 days ago

Regeneron CEO on deal with Trump admin to lower drug prices


FDA Approves First-Ever Gene Therapy to Restore Hearing

Apr 23, 2026, 1:42 PM EDT - 19 days ago

FDA Approves First-Ever Gene Therapy to Restore Hearing


FDA grants accelerated approval for Regeneron’s Otarmeni

2026-04-23T16:45:17.000Z - 19 days ago

FDA grants accelerated approval for Regeneron’s Otarmeni


FDA approves Regeneron's gene therapy for inherited deafness

Apr 23, 2026, 12:45 PM EDT - 19 days ago

FDA approves Regeneron's gene therapy for inherited deafness


Regeneron price target raised to $960 from $880 at TD Cowen

2026-04-23T12:37:10.000Z - 20 days ago

Regeneron price target raised to $960 from $880 at TD Cowen


Regeneron Pharmaceuticals Transcript: Status update

Apr 22, 2026, 8:30 AM EDT - 21 days ago

Regeneron Pharmaceuticals Transcript: Status update


Regeneron Announces Investor Conference Presentations

Apr 20, 2026, 4:05 PM EDT - 22 days ago

Regeneron Announces Investor Conference Presentations


Regeneron says it expects to avoid new US pharma tariffs

Apr 2, 2026, 2:27 PM EDT - 5 weeks ago

Regeneron says it expects to avoid new US pharma tariffs


Regeneron Pharmaceuticals Earnings Call Transcript: Q4 2025

Jan 30, 2026, 8:30 AM EST - 3 months ago

Regeneron Pharmaceuticals Earnings Call Transcript: Q4 2025


Regeneron beats quarterly profit estimates on Dupixent strength

Jan 30, 2026, 7:37 AM EST - 3 months ago

Regeneron beats quarterly profit estimates on Dupixent strength


Regeneron Pharmaceuticals Transcript: Study Update

Dec 10, 2025, 8:30 AM EST - 5 months ago

Regeneron Pharmaceuticals Transcript: Study Update


OfficialStocktwitsUser
OfficialStocktwitsUser May. 13 at 4:41 AM
$REGN RSI: 43.88, MACD: -10.9968 Vol: 22.57, MA20: 728.76, MA50: 746.12 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
bnglao24
bnglao24 May. 12 at 12:24 PM
$IMMX Mgt is comparing nxc-201 to Abbvie’s ententamig in the corporate presentation but looks like they should be aware of $REGN linvoseltamab which is slated for an ASCO oral presentation in a few weeks (also a bispecific) https://www.asco.org/abstracts-presentations/268071 Abstract made public next Thursday 👀
2 · Reply
NewEarth
NewEarth May. 11 at 10:21 PM
0 · Reply
BillionerOfKing
BillionerOfKing May. 11 at 3:11 PM
$REGN Current Stock Price: $718.85 Contracts to trade: $720.0 REGN May 15 2026 Call Entry: $12.40 Exit: $16.12 ROI: 30% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
PickAlpha
PickAlpha May. 11 at 11:59 AM
3/6: MoonLake (MLTX) reports positive final pre‑BLA FDA meeting for sonelokimab (SLK) in hidradenitis suppurativa; plans BLA submission end‑Sep 2026 and seeks Priority Review. $MLTX $XBI $IBB $REGN $VRTX
0 · Reply
WallStJesus
WallStJesus May. 10 at 6:17 PM
$REGN 💉
0 · Reply
Kool_Aid_Mann
Kool_Aid_Mann May. 8 at 7:53 PM
$VRTX $ALNY $REGN Join MNKD as they approach their May 29th pediatric PDUFA!! This is the one that they have been waiting for for 12 years. Lots of delays, but finally here and likely to be the milestone trigger for a big cash deal with big pharma! On top of that, they just got back the green light for Treprostinil DPI in IPF which had them previously trading over $6 until a spat with their partner UTHR. Now, not only is everything copacetic again, but they have also just announced a new molecule colloboration with bigger potential than Trep, Ralinpag DPI! Big royalty model like $LGND But wait, there's more, there is another PDUFA ahead for them for furoscix on July 26th, that will approve a new auto injector that will make this product best in class and reduce COGs by 70% to create massive profits. And lets not forget that nintedabib DPI just finished 1b and is prime for an upfront cash deal! $VCYT Fireworks ahead, fight the Citadel!
0 · Reply
WallStJesus
WallStJesus May. 8 at 2:43 PM
$REGN NOV BULL SWEEPER DETECTED
0 · Reply
NewEarth
NewEarth May. 8 at 2:34 PM
$NTLA $BEAM $EDIT $REGN $PRME Jennifer and Intellia are going to hold the market of all these treatments
0 · Reply
judgeyoung2
judgeyoung2 May. 7 at 7:26 PM
$REGN if fianlimab is disappointing then they’ll prolly drop it on a friday morning
1 · Reply
logn
logn May. 7 at 2:57 AM
$REGN long term still
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed May. 6 at 7:09 PM
$REGN $3B of buybacks going into this quarter- who do you think is going to win the battle?
0 · Reply
LabPsycho
LabPsycho May. 6 at 3:05 PM
$MAIA I am going to keep posting my idea on how to 5X THIO's potential market value until someone takes the baton and runs with it. My antibody ADC-THIO construct shown below based on my computational chemistry and molecular dynamic simulations, and the hypothesis / plausibility is supported by several peer reviewed articles and my own creative, scientifically sound input. In my earlier posts I also describe quick, easy, cost effective pilot studies one could do in a lab in one day to evaluate feasibility. Come on $REGN or $RHHBY - see the light.
1 · Reply
BillionerOfKing
BillionerOfKing May. 6 at 2:59 PM
$REGN Current Stock Price: $722.14 Contracts to trade: $720.0 REGN May 08 2026 Call Entry: $5.90 Exit: $8.61 ROI: 46% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Norbitstock
Norbitstock May. 5 at 8:24 PM
$REGN dont panic. It will rise!! (He told me himself)
0 · Reply
DidYouReadThis
DidYouReadThis May. 5 at 2:49 PM
What was in the news or going on last time $REGN hit a 52 week low? How much (if any) of a dip do you predict if a potential blockbuster competitor receives potential FDA approval in May 2026 or potentially within 1.5 years? Do you think $REGN may dip below 500 within the next 5 years? Do you think opthalmic bevacizumab might receive FDA approval before or after the next presidential election? Do you think OTLK might take a slice of the wet AMD market and more one day? $PFE $LLY $PJP $MRK
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed May. 4 at 3:15 PM
$REGN buybacks at work...
0 · Reply
bzgm
bzgm May. 3 at 6:30 PM
0 · Reply
BioTechHealthX
BioTechHealthX May. 3 at 4:12 PM
$REGN Regeneron Pharmaceuticals, Inc. is gaining fresh momentum as analysts reiterate bullish ratings and highlight upcoming oncology catalysts—here’s why investors are paying attention. https://biotechhealthx.com/biotech-news/is-it-a-great-move-to-acquire-regeneron-pharmaceuticals-regn-shares/
0 · Reply
Edgebell
Edgebell May. 2 at 6:39 PM
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed May. 1 at 2:03 PM
$REGN institutions are accumulating here.
0 · Reply
BioTechHealthX
BioTechHealthX May. 1 at 5:10 AM
$ARWR $CORT $PTCT $REGN $VRTX Biotech is entering a new growth phase fueled by innovation and capital inflows. Here are the top 5 biotech stocks to buy now based on analyst ratings, profitability, and strategic positioning. https://biotechhealthx.com/biotech-news/top-5-best-biotech-stocks-wall-street-is-buying-aggressively-now/
0 · Reply